MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

33.82 1.5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.32

Max

34.23

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+60.91% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	941M 2.6B
Ankstesnė atidarymo kaina	32.32
Ankstesnė uždarymo kaina	33.82

Naujienos nuotaikos

By Acuity

100%

339 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First-Quarter Net Rose on Strong Demand

2026-04-15 23:14; UTC

Uždarbis

Battery Maker CATL First Quarter Net Rose On Strong Demand

2026-04-15 17:13; UTC

Pagrindinės rinkos jėgos

Tesla Shares Rise on Completion of AI5 Chip Design Process

2026-04-15 23:39; UTC

Rinkos pokalbiai

Nikkei May Rise After Gains on Wall Street -- Market Talk

2026-04-15 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

2026-04-15 22:41; UTC

Uždarbis

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

2026-04-15 22:38; UTC

Uždarbis

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

2026-04-15 22:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-15 22:15; UTC

Rinkos pokalbiai

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

2026-04-15 22:14; UTC

Uždarbis

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

2026-04-15 22:12; UTC

Uždarbis

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

2026-04-15 22:11; UTC

Uždarbis

Lens Technology Swings to Loss in 1Q>300433.SZ

2026-04-15 22:07; UTC

Uždarbis

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

2026-04-15 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Skild AI Acquires Zebra Technologies' Robotics Automation Business

2026-04-15 21:29; UTC

Karštos akcijos

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

2026-04-15 20:50; UTC

Rinkos pokalbiai

Uždarbis

Financial Services Roundup: Market Talk

2026-04-15 20:30; UTC

Uždarbis

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

2026-04-15 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-15 20:06; UTC

Rinkos pokalbiai

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

2026-04-15 19:46; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

2026-04-15 19:25; UTC

Rinkos pokalbiai

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

2026-04-15 19:00; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

2026-04-15 18:58; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

2026-04-15 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

2026-04-15 17:45; UTC

Įsigijimai, susijungimai, perėmimai

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

2026-04-15 16:58; UTC

Uždarbis

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

2026-04-15 16:52; UTC

Uždarbis

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

2026-04-15 16:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

2026-04-15 16:37; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

60.91% į viršų

12 mėnesių prognozė

Vidutinis 54.5 USD 60.91%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

11 ratings

Pirkti

Laikyti

Parduoti

Remiantis 11 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.